
Sanofi steps up with a $645M deal to partner with AstraZeneca on a late-stage RSV antibody
Pointing directly at a pivotal Phase III program, AstraZeneca has decided to partner with Sanofi on an experimental antibody for RSV.
The French pharma giant is paying €120 million upfront and up to €495 million more in development and sales milestones to buy into the program. The two Big Pharmas will now split R&D costs for MEDI8897, with AstraZeneca in charge of manufacturing and Sanofi Pasteur taking control of the commercialization work — provided it goes through to an approval.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters